v3.24.1.u1
CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
shares in Thousands, $ in Thousands
3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Total net revenue $ 156,240 $ 137,220
COST OF REVENUE 90,771 82,406
GROSS PROFIT 65,469 54,814
Operating expenses:    
General and administrative 65,797 61,549
Research and development 7,620 7,395
Sales and marketing 20,221 16,259
Restructuring charges 2,398 4,684
Total operating expenses 96,036 89,887
LOSS FROM OPERATIONS (30,567) (35,073)
Interest income (4,834) (3,224)
Interest expense 1,685 1,757
Other expense (income), net 263 114
Loss before taxes (27,681) (33,720)
Income tax benefit (620) (2,925)
NET LOSS $ (27,061) $ (30,795)
NET LOSS PER SHARE    
Basic (in dollars per share) $ (0.21) $ (0.25)
Diluted (in dollars per share) $ (0.21) $ (0.25)
WEIGHTED AVERAGE COMMON SHARES OUTSTANDING    
Basic (in shares) 126,111 125,026
Diluted (in shares) 126,111 125,026
Clinical Services    
Total net revenue $ 134,535 $ 114,869
COST OF REVENUE 76,844 67,292
GROSS PROFIT 57,691 47,577
Advanced Diagnostics    
Total net revenue 21,705 22,351
COST OF REVENUE 13,927 15,114
GROSS PROFIT $ 7,778 $ 7,237

Source